

Frank W Rockhold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8967915/publications.pdf>

Version: 2024-02-01

102
papers

8,608
citations

218677

26
h-index

48315

88
g-index

108
all docs

108
docs citations

108
times ranked

16560
citing authors

#	ARTICLE	IF	CITATIONS
1	The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 29-42.	0.8	19
2	The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 43-56.	0.8	32
3	Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 3-13.	0.8	24
4	Institutional approaches to preventing questionable research practices. <i>Accountability in Research</i> , 2023, 30, 252-259.	2.4	2
5	Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey. <i>JMIR Medical Informatics</i> , 2022, 10, e30363.	2.6	21
6	Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2022, 399, 461-472.	13.7	69
7	Clinical events classification (CEC) in clinical trials: Report on the current landscape and future directions “ proceedings from the CEC Summit 2018. <i>American Heart Journal</i> , 2022, 246, 93-104.	2.7	3
8	Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World. <i>Clinical Therapeutics</i> , 2022, 44, 420-437.	2.5	36
9	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. <i>Journal of the American Heart Association</i> , 2022, 11, e022003.	3.7	6
10	COVID-19 Trials: Who Participates and Who Benefits?. <i>Southern Medical Journal</i> , 2022, 115, 256-261.	0.7	2
11	The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. <i>Contemporary Clinical Trials</i> , 2022, 115, 106732.	1.8	2
12	Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 990-1001.	9.1	16
13	Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1781-1783.	2.8	1
14	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	4
15	Myocardial Infarction in the ISCHEMIA Trial. <i>Circulation</i> , 2021, 143, 790-804.	1.6	81
16	A randomized, open-label, pragmatic study to assess reliever-triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: Design and methods of the PREPARE trial. <i>Contemporary Clinical Trials</i> , 2021, 101, 106246.	1.8	14
17	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. <i>International Journal of COPD</i> , 2021, Volume 16, 841-851.	2.3	6
18	Effect of COVID-19 on asthma exacerbation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2896-2899.e1.	3.8	31

#	ARTICLE	IF	CITATIONS
19	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	12.8	194
20	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	3.9	30
21	What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , 2021, 42, 2373-2383.	2.2	9
22	Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2021, 26, 1358863X2110176.	1.5	0
23	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. <i>Journal of the American Heart Association</i> , 2021, 10, e018684.	3.7	13
24	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009871.	3.9	2
25	Primary and Secondary Outcome Reporting in Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2021, 78, 827-839.	2.8	28
26	World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2021, , 1358863X2110386.	1.5	2
27	Open Science to Address COVID-19: Sharing Data to Make Our Research Investment Go Further. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 558-560.	1.6	5
28	Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. <i>American Heart Journal</i> , 2020, 220, 51-58.	2.7	8
29	Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009326.	3.9	7
30	Cause of Death Among Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006550.	2.2	10
31	Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job. <i>Annals of Internal Medicine</i> , 2020, 172, 119.	3.9	18
32	CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. <i>American Heart Journal</i> , 2020, 229, 118-120.	2.7	2
33	Adaptive trial designs for spinal cord injury clinical trials directed to the central nervous system. <i>Spinal Cord</i> , 2020, 58, 1235-1248.	1.9	17
34	Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006512.	2.2	16
35	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. <i>Circulation</i> , 2020, 142, 1725-1735.	1.6	77
36	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq0 0 0 rgBTJ/Overlock 10 Tf 50 e016573.	3.7	7

#	ARTICLE	IF	CITATIONS
37	The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and Postoperative Cognitive Dysfunction. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1319-1328.	2.6	11
38	Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1477-1488.	1.6	11
39	A Framework for Safety Evaluation Throughout the Product Development Life-Cycle. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 821-830.	1.6	7
40	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	27.0	1,508
41	Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006399.	2.2	23
42	Design and analytic considerations for using patient-reported health data in pragmatic clinical trials: report from an NIH Collaboratory roundtable. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 634-638.	4.4	10
43	Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 608-617.	2.8	30
44	Time for NIH to lead on data sharing. <i>Science</i> , 2020, 367, 1308-1309.	12.6	42
45	Pragmatic Randomized Trials Using Claims or Electronic Health Record Data. , 2020, , 1-11.		4
46	University of Pennsylvania 11th annual conference on statistical issues in clinical trials: Estimands, missing data and sensitivity analysis (morning panel session). <i>Clinical Trials</i> , 2019, 16, 350-362.	1.6	3
47	Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. <i>Vascular Medicine</i> , 2019, 24, 422-430.	1.5	13
48	Open science: The open clinical trials data journey. <i>Clinical Trials</i> , 2019, 16, 539-546.	1.6	24
49	Impact of Procedural Bleeding in Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008069.	3.9	6
50	Acute Limb Ischemia in Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 556-565.	1.6	80
51	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	6.1	9
52	Stroke in Patients With Peripheral Artery Disease. <i>Stroke</i> , 2019, 50, 1356-1363.	2.0	33
53	Natural History and Outcomes of Patients with Critical Limb Ischemia in the Euclid Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, e117-e118.	1.5	0
54	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2019, 4, 7.	6.1	26

#	ARTICLE	IF	CITATIONS
55	Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 109-117.	1.5	28
56	Transforming the future of health together: The Learning Health Systems Consensus Action Plan. <i>Learning Health Systems</i> , 2018, 2, e10055.	2.0	17
57	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3274-3284.	2.8	64
58	Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease. <i>JAMA Network Open</i> , 2018, 1, e185239.	5.9	68
59	Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1563-1572.	2.8	39
60	Finding Means to Fulfill the Societal and Academic Imperative for Open Data Access and Sharing. <i>JAMA Cardiology</i> , 2018, 3, 793.	6.1	5
61	Deriving Real-World Insights From Real-World Data: Biostatistics to the Rescue. <i>Annals of Internal Medicine</i> , 2018, 169, 401.	3.9	9
62	Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2018, 23, 523-530.	1.5	29
63	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet</i> , 2017, 389, 1799-1808.	13.7	174
64	Comments on "Estimands in clinical trials" broadening the perspective™. <i>Statistics in Medicine</i> , 2017, 36, 24-26.	1.6	0
65	Statistical controversies in clinical research: data access and sharing" can we be more transparent about clinical research? Let's do what's right for patients. <i>Annals of Oncology</i> , 2017, 28, 1734-1737.	1.2	5
66	Data Sharing at a Crossroads. <i>New England Journal of Medicine</i> , 2016, 375, 1115-1117.	27.0	49
67	SPIRIT 2013 Statement: defining standard protocol items for clinical trials. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2015, 38, 506-14.	1.1	114
68	Bumps and bridges on the road to responsible sharing of clinical trial data. <i>Clinical Trials</i> , 2014, 11, 7-12.	1.6	27
69	Access to Patient-Level Data from GlaxoSmithKline Clinical Trials. <i>New England Journal of Medicine</i> , 2013, 369, 475-478.	27.0	112
70	SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. <i>Annals of Internal Medicine</i> , 2013, 158, 200.	3.9	4,463
71	10 Years with ICH E10: Choice of Control Groups. <i>Pharmaceutical Statistics</i> , 2011, 10, 407-409.	1.3	4
72	Statisticians in the Pharmaceutical Industry: The 21st Century. <i>Statistics in Biopharmaceutical Research</i> , 2010, 2, 145-152.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Public disclosure of clinical research. <i>Lancet, The</i> , 2009, 373, 1319-1320.	13.7	8
74	ICH-E9 reflections and considerations. <i>Pharmaceutical Statistics</i> , 2008, 7, 233-235.	1.3	5
75	Reporting the findings of clinical trials: a discussion paper. <i>Bulletin of the World Health Organization</i> , 2008, 2008, 492-493.	3.3	30
76	The GSK Clinical Study Results Database: Site Utilization Metrics for a Large Public Database. <i>Drug Information Journal</i> , 2008, 42, 247-252.	0.5	0
77	Electronic Health Records, Medical Research, and the Tower of Babel. <i>New England Journal of Medicine</i> , 2008, 358, 1738-1740.	27.0	79
78	Trial summaries on results databases and journal publication. <i>Lancet, The</i> , 2006, 367, 1635-1636.	13.7	9
79	Reasons for optimism not disillusionment. <i>Journal of the Royal Society of Medicine</i> , 2006, 99, 435-435.	2.0	2
80	Requiring "independent" statistical analyses for industry sponsored trials?. <i>Pharmaceutical Statistics</i> , 2006, 5, 5-6.	1.3	5
81	Clinical Trials Registration. <i>PLoS Medicine</i> , 2006, 3, e157.	8.4	4
82	The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients. <i>Clinical Trials</i> , 2006, 3, 154-157.	1.6	18
83	Trial Registration: Ignored to Irresistible. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 158.	7.4	1
84	The Society for Clinical Trials supports United States legislation mandating trials registration. <i>Clinical Trials</i> , 2005, 2, 193-193.	1.6	1
85	More on compulsory registration of clinical trials: GSK has created useful register. <i>BMJ: British Medical Journal</i> , 2005, 330, 479.3-480.	2.3	9
86	Liability issues for data monitoring committee members. <i>Clinical Trials</i> , 2004, 1, 525-531.	1.6	37
87	Issues in regulatory guidelines for data monitoring committees. <i>Clinical Trials</i> , 2004, 1, 162-169.	1.6	21
88	Industry perspectives on ICH guidelines. <i>Statistics in Medicine</i> , 2002, 21, 2949-2957.	1.6	7
89	Strategic use of statistical thinking in drug development. <i>Statistics in Medicine</i> , 2000, 19, 3211-3217.	1.6	8
90	Guidelines for Quality Assurance in Multicenter Trials. <i>Contemporary Clinical Trials</i> , 1998, 19, 477-493.	1.9	106

#	ARTICLE	IF	CITATIONS
91	An approach to the assessment of therapeutic drug interactions with fixed combination drug products. <i>Journal of Biopharmaceutical Statistics</i> , 1996, 6, 231-240.	0.8	8
92	Data monitoring and interim analyses in the pharmaceutical industry: Ethical and logistical considerations. <i>Statistics in Medicine</i> , 1993, 12, 471-479.	1.6	16
93	Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. <i>Critical Care Medicine</i> , 1993, 21, 19-30.	0.9	163
94	Cimetidine 800 mg Twice Daily for Healing Erosions and Ulcers in Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 1990, 12, S29-S34.	2.2	25
95	Comparison of Cimetidine and Placebo for the Prophylaxis of Upper Gastrointestinal Bleeding Due to Stress-related Gastric Mucosal Damage in the Intensive Care Unit. <i>Journal of Intensive Care Medicine</i> , 1990, 5, 26-32.	2.8	44
96	Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 208-218.	4.7	16
97	Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 234-239.	4.7	8
98	Monitoring versus interim analysis of clinical trials: A perspective from the pharmaceutical industry. <i>Contemporary Clinical Trials</i> , 1989, 10, 57-70.	1.9	26
99	Clinical Pharmacokinetics of Pinacidil, A Potassium Channel Opener, in Hypertension. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 33-40.	2.0	11
100	Vasodilator monotherapy in the treatment of hypertension: Comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 78-92.	4.7	24
101	Cellular Electrophysiology of Clofilium, a New Antifibrillatory Agent, in Normal and Ischemic Canine Purkinje Fibers. <i>Journal of Cardiovascular Pharmacology</i> , 1981, 3, 881-895.	1.9	29
102	Understanding Study Drug Discontinuation Through EUCLID. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2